NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners

Regulatory agencies have emphasized the uniqueness and originality of the NFL-101 approach. The forthcoming results, aimed at confirming this distinctive scientific positioning, are of particular importance to interested pharmaceutical companies.

Upcoming scientific milestones

• Mechanism of action (MOA) in January 2026: preliminary results from a proteomic analysis aimed to identify neural and immune signalling markers induced by NFL-101, to compare them with those involved in tobacco dependence to further elucidate its MOA and demonstrate that these original characteristics clearly and meaningfully distinguish NFL-101 from all existing smoking cessation products.

• In-depth characterisation in December 2025:first results from additional analyses of the composition of NFL-101, designed to further characterize the extracts and confirm inter-batch reproducibility.

Context

These studies are part of the roadmap announced on October 20, 2025, which includes additional work on the composition and mechanism of action of NFL-101.

About NFL Biosciences: www.nflbiosciences.com

NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.

NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an “Innovative Company” eligible for FCPI investment. More information on www.nflbiosciences.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251111593795/en/